Atrophic gastritis, also known as chronic atrophic gastritis, is a disease characterized by atrophy of the epithelium and glands of the gastric mucosa, a decrease in number, thinning of the gastric mucosa, thickening of the mucosal base, or with pyloric glandular hyperplasia and intestinal glandular hyperplasia, or with atypical hyperplasia. The most serious consequence of atrophic gastritis is the development of gastric cancer. Atrophic gastritis is divided into non-chemotropic atrophy and chemoatropic atrophy depending on whether it is accompanied by chemosis. The risk of developing gastric cancer is increased by multifocal atrophy centered on the gastric horn and spreading to the sinus and body of the stomach. In the progression of chronic inflammation to gastric cancer, atrophy to intestinal chemosis to heterogeneous hyperplasia to gastric cancer is considered as the progression of gastric cancer. In terms of prognostic treatment, generally chronic non-atrophic gastritis has a good prognosis, and intestinal epithelial hyperplasia is usually difficult to reverse; atrophy can be improved or reversed in some patients. Therefore, it is recommended to develop good dietary habits, eat a soft, easily digestible diet, avoid too rough, and avoid eating foods with strong and spicy seasonings or taking drugs that are stimulating to the stomach. If the symptoms of atrophic gastritis appear, treatment should be actively carried out under the guidance of a clinician to eradicate Helicobacter pylori and change the diet, which can slow down the development of atrophic gastritis to avoid aggravation of the disease.